BRISBANE: CareDx Inc. has agreed to acquire precision oncology diagnostics company Naveris for up to $260 million, expanding its testing services beyond transplant medicine into cancer monitoring.
The deal includes $160 million in upfront cash and up to $100 million tied to revenue milestones, the companies said. The transaction is expected to close in the third quarter of 2026, subject to customary conditions.
CareDx, which focuses on precision medicine solutions for transplant patients, said the acquisition supports its strategy to grow its U.S. precision medicine testing services and digital health offerings. Naveris markets a Medicare-reimbursed, blood-based test used to monitor viral-mediated cancers and detect molecular residual disease, or MRD.
Naveris’ platform is based on Tumor Tissue Modified Viral (TTMV) DNA technology, which measures fragments of viral DNA shed by tumor tissue into the bloodstream. The approach is used primarily in human papillomavirus (HPV)-driven cancers, including head and neck and anal cancers, to monitor patients after treatment.
Naveris reported unaudited revenue of $34 million for 2025 and projects annual growth of 30% to 40% over the next three years, CareDx said. For the first quarter of 2026, Naveris reported approximately $12 million in revenue, 65% gross margins and a net operating loss of about $200,000.
CareDx said the acquisition is not expected to affect its fiscal year 2026 adjusted EBITDA guidance. The company plans to provide updated guidance after the transaction closes.
Naveris employs about 100 people and has performed more than 130,000 commercial tests to date. Its NavDx test received Medicare coverage in 2023.
CareDx said the deal gives it entry into a specialty oncology market it estimates at $4.5 billion.
Goldman Sachs is advising CareDx on the transaction, while J.P. Morgan Securities LLC is advising Naveris.
Editor’s Commentary: This acquisition marks a significant strategic pivot for CareDx, signaling a willingness to look beyond its established niche in transplant genomics toward the competitive field of oncology diagnostics. By integrating Naveris, CareDx is not only diversifying its revenue streams but also entering a high-growth segment of precision medicine driven by viral cancers.
The financial structure of the deal highlights the confidence institutional buyers have in Naveris’ existing market traction. With $34 million in projected 2025 revenue already realized—and a clear path to Medicare reimbursement—the company offers an immediate cash flow engine rather than a speculative pipeline asset. For the biotech sector, this transaction underscores a broader trend: mature diagnostic firms are increasingly being acquired by larger platforms seeking to scale their testing services portfolios quickly.
Investors should watch closely how CareDx integrates Naveris’ molecular residual disease (MRD) platform with its existing digital health tools. If successfully combined, the hybrid model could create a robust infrastructure for managing patient data across multiple therapeutic areas, potentially setting a precedent for future consolidation in the U.S. clinical laboratory space. However, the timeline to close—Q3 2026—leaves ample room for regulatory or integration hurdles that could impact the anticipated growth trajectory.